News & media

Here you can find news and media resources. To comply with applicable regulation in Denmark, press releases and company announcements concerning specific medicinal products or investigational candidates in late-stage development are removed from our website within three weeks of publication. Please contact us to request a copy.

  • COMPANY ANNOUNCEMENT

    Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants

  • COMPANY ANNOUNCEMENT

    Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis

  • COMPANY ANNOUNCEMENT

    Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL

  • PRESS RELEASE

    Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency

  • PRESS RELEASE

    Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024

  • COMPANY ANNOUNCEMENT

    Zealand Pharma major shareholder announcement: Polar Capital

  • COMPANY ANNOUNCEMENT

    Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide

  • COMPANY ANNOUNCEMENT

    Zealand Pharma Announces Financial Results for the First Quarter of 2024

  • COMPANY ANNOUNCEMENT

    Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

  • PRESS RELEASE

    Zealand Pharma conference call on May 16 at 2pm CET (8am ET) to present first quarter 2024 financial results

  • COMPANY ANNOUNCEMENT

    Correction to Company announcement – No. 23 / 2024

  • COMPANY ANNOUNCEMENT

    Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Corporate management

  • Adam ALR0640

    Adam Steensberg - President and Chief Executive Officer

  • Zealand Pharma 0285 FIN

    Adam Steensberg - President and Chief Executive Officer

  • Christina ALR0693 V2

    Christina Sonnenborg Bredal - Executive Vice President and Chief People Officer

  • David ALR1003

    David Kendall - Executive Vice President, Research & Development and Chief Medical Officer

  • Henriette ALR0758

    Henriette Wennicke - Executive Vice President and Chief Financial Officer

  • Ivan ALR0873

    Ivan Møller - Executive Vice President and Chief Operating Officer

  • Ravinder ALR0732

    Ravinder Chahil - Executive Vice President and General Counsel

Research and development

Logos and icons

Zealand Pharma 1503

Stay up-to-date with the latest news from Zealand

Sign-up to receive press releases and company announcements directly to your inbox

Subscribe to news

Investor and Media contacts

  • Anna ALR0858

    Anna Krassowska

    Vice President, Investor Relations & Corporate Communications

    Email Anna